Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: Behavioral and neurochemical studies in the rat

Neurotoxicity Research

Volumn 26, Issue 1, 2014, Pages 85-98

  Antkiewicz Michaluk, Lucyna ^a   Wąsik, Agnieszka ^a   Możdżeń, Edyta ^a   Romańska, Irena ^a   Michaluk, Jerzy ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Brain structures; Depression reserpine model; Forced swim test; Monoamines metabolism; Rat; Tetrahydroisoquinolines

Indexed keywords

1 METHYL TETRAHYDROISOQUINOLINE DERIVATIVE; 3 O METHYLDOPAMINE; ANTIDEPRESSANT AGENT; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; MONOAMINE; NORADRENALIN; NORMETADRENALIN; RESERPINE; SEROTONIN; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER; 1,2,3,4-TETRAHYDROISOQUINOLINE; 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN REGION; CATABOLISM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DRUG STRUCTURE; FORCED SWIM TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOTHALAMUS; LOCOMOTION; MALE; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; OXIDATION; PRIORITY JOURNAL; RAT; VENTRAL TEGMENTUM; ANIMAL; CHEMISTRY; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALIA; MAMMALIA; RATTUS; RODENTIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOPAMINE; HYPOTHALAMUS; MALE; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; NOREPINEPHRINE; NUCLEUS ACCUMBENS; RATS, WISTAR; RESERPINE; SEROTONIN; TETRAHYDROISOQUINOLINES;

EID: 84903781446     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9454-8     Document Type: Article

References (48)

1. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romańska I, Lorenc-Koci E, Otha S, Vetulani J (2001) Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem 78:100-108 (Pubitemid 32622592)
2. Antkiewicz-Michaluk L, Lazarewicz JW, Patsenka A, Kajta M, Zieminska E, Salinska E, Wasik A, Golembiowska K, Vetulani J (2006) The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 97:846-856
3. Antkiewicz-Michaluk L, Wa̧sik A, Michaluk J (2014) 1-Methyl- 1,2,3,4-tetrahydroisoquinoline, an endogenous amine with unexpected mechanism of action: new vistas of therapeutic application. Neurotox Res 25:1-12
4. Borsini F (1995) Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 19:377-395
5. Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147-160 (Pubitemid 18040687)
6. Cantello R, Aguggia M, Gilli M, Delsedime M, Cutin IC, Riccio A, Mutani R (1989) Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J Neurol Neurosurg Psychiatry 52:724-731 (Pubitemid 19165637)
7. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormak AL et al (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27:8138-8148 (Pubitemid 47173329)
8. Caudle WM, Colebrooke RE, Emson PC, Miller GW (2008) Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 31:303-308
9. Chan-Palay V, Asan E (1989) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287:373-392 (Pubitemid 19239069)
10. Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rats. Neuropharmacology 26:1431-1440
11. Cryan JF, Lucki I (2000) Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine(2C) receptors. J Pharmacol Exp Ther 295:1120-1126
12. Cryan JF, Page ME, Lucki I (2005) Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacol 182:335-344 (Pubitemid 41464645)
13. Detke MJ, Lucki I (1996) Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav Brain Res 73:43-46 (Pubitemid 26007585)
14. Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotoninergic and noradrenergic antidepressants. Psychopharmacol (Berl). 121:66-72
15. Elhwuegi AS (2004) Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 28:435-451
16. Fernandes VS, Ribeiro AM, Melo TG, Godinho M, Barbosa FF, Medeiros DS (2008) Memory impairment induced by low doses of reserpine in rats: possible relationship with emotional processing deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 32:1479-1483
17. Fernandes VS, Santos JR, Leao A, Medeiros A, Melo TG, Izidio GS, Cabral A, Ribeiro RA et al (2012) Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease. Behav Brain Res 231:154-163
18. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041 (Pubitemid 26383833)
19. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643
20. Grunewald GL, Reitz TJ, Ruth JA, Vollmer S, Eiden LE, Ruthedge CO (1979) Inhibition of neuronal uptake of 3H-biogenic amines rat cerebral cortex by partially and fully saturated derivatives of imipramine and desipramine. The importance of the aromatic ring in adrenergic amines - Part 3. Biochem Pharmacol 28: 417-421
21. Javaid JI, Perel JM, Davis JM (1979) Inhibition of biogenic amines uptake by imipramine, desipramine, 2 OH-imipramine and 2 OH-desipramine in rat brain. Life Sci 24:21-28 (Pubitemid 9107782)
22. Kandel ER (2000) Disorders of mood: depression, mania, and anxiety disorders. In: Kandel ER (ed) Principles of neural science, 4th edn. McGraw-Hill Companies, New York, pp 1216-1217
23. Kodydkova J, Vavrova L, Zeman M, Jirak R, Macasek J, Stankova B, Tvrzicka E, Zak A (2009) Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 42: 1368-1374
24. Kotake Y, Tasaki Y, Makino Y, Otha S, Hirobe M (1995) 1-Benzyl- 1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 65:2633-2638
25. Liu Y, Peter D, Roghani A (1992) cDNA that suppresses MPP toxicity encodes a vesicular amine transporter. Cell 70:539-551
26. Maes M (2008) The cytokine hypothesis of depression: inflammation, oxidative and nitrosative stress and leaky gut as a new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 29:287-291
27. Maes M, Galecki P, Chang YS, Berk M (2011) A review on the oxidative and nitrosative stress pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Progress in NeuroPsychopharmacol Biol Psychiatry 35:676-692
28. Makino Y, Tasaki Y, Ohta S, Hirobe M (1990) Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization. Biomed Environ Mass Spectrom 19:415-419 (Pubitemid 20335928)
29. Mayeux R, Stern Y, Cote L, Williams JB (1984) Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 39:642-646 (Pubitemid 14143522)
30. McNaught KS, Carrupt PA, Altomare C, Cellamare S et al (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol 56:921-933 (Pubitemid 28454556)
31. Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999) Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424-429 (Pubitemid 29450365)
32. Murray F, Smith DW, Huston PH (2008) Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviors in mice. Eur J Pharmacol 583:115-127
33. Nagakura Y, Oe T, Aoki T, Matsuoka N (2009) Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 146:26-33
34. Naoi M, Maruyama W (1993) Type B monoamine oxidase and neurotoxins. Eur Neurol 33:31-37 (Pubitemid 23235374)
35. Patsenka A, Antkiewicz-Michaluk L (2004) Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds - 1,2,3,4-tetrahydroisoquinoline alkaloids. Pol J Pharmacol 56:727-734 (Pubitemid 40287474)
36. Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioural despair test in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391
37. Rojas-Corrales MO, Berrocoso E, Gibert-Rahola J, Mico JA (2004) Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates. J Psychopharmacol 18:404-411 (Pubitemid 39382569)
38. Rommelspacher H, Susilo R (1985) Tetrahydroisoquinolines and β-carbolines: putative natural substances in plants and mammals. Prog Drug Res 29:415-459 Birkhäuser Verlag Basel (Pubitemid 16165832)
39. Singer TP, Ramsay RR (1995) Flavoprotein structure and mechanism 2. Monoamine oxidases: old friends hold many surprises. FASEB J 9:605-610
40. Surratt CK, Persico AM, Yang DX (1993) A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs. FEBS Lett 318:325-330 (Pubitemid 23071763)
41. Tasaki Y, Makino Y, Ohta S, Hirobe M (1991) 1-Methyl-1,2,3,4- tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J Neurochem 57:1940-1943 (Pubitemid 21922843)
42. Taylor TN, Caudle WM, Shepherd KR (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29:8103-8113
43. Uhl GR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43:555-560
44. Vetulani J, Nalepa I (2000) Antidepressants: past, present and future. Eur J Pharmacol 405:351-363
45. Wa̧sik A, Romańska I, Antkiewicz-Michaluk L (2009) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous parkinsonisminducing toxin, strongly potentiates MAO-dependent dopamine oxidation and impairs dopamine release: ex vivo and in vivo neurochemical studies. Neurotox Res 15:15-23
46. Wa̧sik A, Możdżeń E, Romańska I, Michaluk J, Antkiewicz-Michaluk L (2013) Antidepressant-like activity of an endogenous amine, 1-methyl-1,2,3,4-tetrahydroisoquinoline in the behavioral despair test in the rat, and its neurochemical correlates: a comparison with the classical antidepressant, imipramine. Eur J Pharmacol 700:110-117
47. Zhao Y, Ma R, Shen J, Su H, Xing D, Du L (2008) A mouse model of depression induced by repeated corticosterone injections. Eur J Pharmacol 581:113-120
48. Ziemssen T, Reichmann H (2007) Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 13:323-332 (Pubitemid 47212791)